Preliminary results of the STOP-COVID19 trial are now available. The objective of this 28-day study was to test whether Brensocatib when added to standard of care could improve clinical status compared to standard of care alone in severe patients hospitalized with COVID-19. The study recruited 406 patients across 14 UK hospitals. Preliminary results did not show evidence of clinical benefit on the primary and key secondary outcomes of clinical status and time to clinical improvement. However, a robust effect on the main target of neutrophil serine proteases was seen, and no significant difference in adverse events was observed between groups. Further data will be shared in the form of a scientific publication in the coming months.